A RCT Study in Schizophrenia Relapse Prevention

NCT ID: NCT01885923

Last Updated: 2013-07-12

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 150 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-08-31
• Study Completion Date: 2015-12-31

Brief Summary

THE AIM OF THE PROJECT The main aim lies in the prevention of frequent relapses typical for schizophrenia and schizoaffective disorder by means of simple, highly cost-effective information technology-aided approach RESEARCH HYPOTHESIS A the end of 18 months study duration, patients in the active group enrolled in ITAREPS will demonstrate statistically significantly reduced risk of hospitalization, decreased number of hospitalization days and reduced direct inpatient costs in comparison to control group not using the program.

Detailed Description

The ITAREPS 2.0 program employs telecommunication and information technologies in order to detect fluctuations in longitudinal mental health status of patient with schizophrenia and thus signalize the very early stages of prodromes preceding relapse. This approach opens an avenue towards early pharmacological intervention. Subjects (150 patients with diagnosis of schizophrenia and schizoaffective disorder and their family members) will be randomized at a 1:1 ratio into the active or control group. Participants from the active group will be completing two separate versions of the 10-item Early Warning Signs Questionnaire (EWSQ) upon a weekly SMS request generated automatically by the system during 18 months study duration. In this group, automatically generated e-mail alert message feedback to the investigator will be activated in case of prodrome detection, prompting investigator to antipsychotic dose increase by 20%. The control (treatment-as-usual) group will not use ITAREPS system.

Conditions

Relapse Schizophrenia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

20% antisychotic dose increase in prodromes

Antipsychotic dose increase upon prodromes occurence detected by Device- ITAREPS system. All antipsychotics currently registered in Czech Republic will be allowed in this study. All patients will remain on antipsychotic treatment adjusted prior enrollment, so that dose adjustment will be based on their ordinary medication. Participants will be instructed to complete the 10-item EWS Questionnaire upon SMS request sent automatically weekly to their mobile phones. EWSQ detects proportional worsening of the symptoms compared to the last week's score of the questionnaire. Individual EWSQ scores will be sent by participants back to the ITAREPS system as a SMS. If the total score exceeds the given score threshold, an immediate ALERT would be declared and announced to the investigator as an e-mail message and a therapeutic intervention is requested. After detecting the early warning signs by ITAREPS, an immediate 20% increase in the dose of antipsychotic will be required.

Group Type: ACTIVE_COMPARATOR

ITAREPS

Intervention Type: DEVICE

Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)

Treatment as usual

In the control group (treatment-as-usual) participants will not be enrolled in the ITAREPS system.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

ITAREPS

Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)

Intervention Type: DEVICE

Other Intervention Names

Information Technology Aided Relaps Prevention in Schizophrenia

Eligibility Criteria

Inclusion Criteria

For entry into the study, the following criteria MUST be met:

• Men and women, ages 18 to 60 years, inclusive.
• A diagnosis of schizophrenia or schizoaffective disorder according to ICD-10 classification.
• Having at least TWO psychiatric hospitalization for psychosis before the study enrollment.
• Severity (CGI-S) ≤ 3 at study Visit 1.
• All patients must be on stable doses of antipsychotic medication during the study entry.

Exclusion Criteria

• Organic mental disorder,
• mental disorder due to psychoactive substance use or mental retardation.
• Participation in another relapse prevention program.
• Hayward compliance rating scale score < 2 at Visit 1.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Prague Psychiatric Center

OTHER_GOV

Sponsor Role: lead

Responsible Party

Filip Spaniel, M.D., Ph.D

MD

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Filip Spaniel, MD, PhD

Role: STUDY_DIRECTOR

Prague Psychiatric Center

Locations

Prague Psychiatric Center

Prague, , Czechia

Countries

Czechia

References

Spaniel F, Novak T, Bankovska Motlova L, Capkova J, Slovakova A, Trancik P, Matejka M, Hoschl C. Psychiatrist's adherence: a new factor in relapse prevention of schizophrenia. A randomized controlled study on relapse control through telemedicine system. J Psychiatr Ment Health Nurs. 2015 Dec;22(10):811-20. doi: 10.1111/jpm.12251. Epub 2015 Jul 14.

Reference Type: DERIVED

PMID: 26176646 (View on PubMed)

Other Identifiers

NT/13292 - 3

Identifier Type: REGISTRY

Identifier Source: secondary_id

ITAREPS 2.0

Identifier Type: -

Identifier Source: org_study_id